Kanasaki S, Furukawa A, Kane T, Murata K
Department of Radiology, Shiga University of Medical Science, Otsu Shiga, Japan.
Cardiovasc Intervent Radiol. 2000 Mar-Apr;23(2):114-20. doi: 10.1007/s002709910023.
To evaluate the clinical efficacy of the polyurethane-covered Nitinol Strecker stent in the treatment of patients with malignant biliary obstruction.
Twenty-three covered stents produced by us were placed in 18 patients with malignant biliary obstruction. Jaundice was caused by cholangiocarcinoma (n = 5), pancreatic cancer (n = 6), gallbladder cancer (n = 4), metastatic lymph nodes (n = 2), and tumor of the papilla (n = 1).
The mean patency period of the stents was 37.5 weeks (5-106 weeks). Recurrent obstructive jaundice occurred in two patients (11%). Adequate biliary drainage over 50 weeks or until death was achieved in 17 of 18 patients (94.4%). Late cholangitis was observed in two patients whose stents bridged the ampulla of Vater. Other late severe complications were not encountered.
Although more study is necessary, our results suggest the clinical efficacy of our covered Nitinol Strecker stent in the management of obstructive jaundice caused by malignant diseases.
评估聚氨酯涂层镍钛诺Strecker支架治疗恶性胆道梗阻患者的临床疗效。
将我们生产的23个覆膜支架置入18例恶性胆道梗阻患者体内。黄疸病因包括胆管癌（5例）、胰腺癌（6例）、胆囊癌（4例）、转移性淋巴结（2例）和乳头肿瘤（1例）。
支架的平均通畅期为37.5周（5 - 106周）。2例患者（11%）出现复发性梗阻性黄疸。18例患者中有17例（94.4%）实现了超过50周或直至死亡的充分胆汁引流。2例支架跨过Vater壶腹的患者出现了迟发性胆管炎。未遇到其他晚期严重并发症。
尽管还需要更多研究，但我们的结果表明我们的覆膜镍钛诺Strecker支架在治疗恶性疾病引起的梗阻性黄疸方面具有临床疗效。
